Tumour necrosis factor a as a therapeutic target for immune-mediated inflammatory diseases

被引：42

作者：

Taylor, PC ^{[1
]}

Williams, RO ^{[1
]}

Feldmann, M ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, Fac Med, London W68LH, England

来源：

CURRENT OPINION IN BIOTECHNOLOGY | 2004年 / 15卷 / 06期

关键词：

D O I：

10.1016/j.copbio.2004.09.005

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Preclinical studies have identified and validated tumour necrosis factor alpha (TNFalpha) as a key disease molecule and therapeutic target for immunotherapeutic intervention in many immune-mediated inflammatory diseases. Clinical indications include rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis. Recent clinical findings indicate that many chronic inflammatory disorders share certain pathogenic pathways, whereas others are limited to particular disease phenotypes. Better understanding of these pathogenic pathways will inform the development of new therapeutic approaches leading to more complete and sustained disease remissions.

引用

页码：557 / 563

页数：7

共 79 条

[1] Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides:: an open pilot study on 10 patients [J].

Bartolucci, P ;

Ramanoelina, J ;

Cohen, P ;

Mahr, A ;

Godmer, P ;

Le Hello, C ;

Guillevin, L .

RHEUMATOLOGY, 2002, 41 (10) :1126-1132

[2]

Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO

[3]

2-E

[4] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

[5] Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab - Evaluation of a new scoring system [J].

Braun, J ;

Baraliakos, X ;

Golder, W ;

Brandt, J ;

Rudwaleit, M ;

Listing, J ;

Bolow, M ;

Sieper, J ;

van der Heijde, D .

ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :1126-1136

[6] USE OF IMMUNOHISTOLOGIC AND IN-SITU HYBRIDIZATION TECHNIQUES IN THE EXAMINATION OF SACROILIAC JOINT BIOPSY SPECIMENS FROM PATIENTS WITH ANKYLOSING-SPONDYLITIS [J].

BRAUN, J ;

BOLLOW, M ;

NEURE, L ;

SEIPELT, E ;

SEYREKBASAN, F ;

HERBST, H ;

EGGENS, U ;

DISTLER, A ;

SIEPER, J .

ARTHRITIS AND RHEUMATISM, 1995, 38 (04) :499-505

[7] Infliximab in active early rheumatoid arthritis [J].

Breedveld, FC ;

Emery, P ;

Keystone, E ;

Patel, K ;

Furst, DE ;

Kalden, JR ;

St Clair, EW ;

Weisman, M ;

Smolen, J ;

Lipsky, PE ;

Maini, RN .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (02) :149-155

[8] TUMOR-NECROSIS-FACTOR ALPHA-PRODUCING CELLS IN THE INTESTINAL-MUCOSA OF CHILDREN WITH INFLAMMATORY BOWEL-DISEASE [J].

BREESE, EJ ;

MICHIE, CA ;

NICHOLLS, SW ;

MURCH, SH ;

WILLIAMS, CB ;

DOMIZIO, P ;

WALKERSMITH, JA ;

MACDONALD, TT .

GASTROENTEROLOGY, 1994, 106 (06) :1455-1466

[9]

Brennan FM, 1997, BRIT J RHEUMATOL, V36, P643

[10]

BRENNAN FM, 1989, LANCET, V2, P244

← 1 2 3 4 5 6 7 8 →